TrialSignal transduction and targeted therapy2026

Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.

Linong Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.